LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

Epigenetic regulators are recurrently mutated and aberrantly expressed in acute myeloid leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes, such as the histone demethylase lysine-specific demethylase 1 (LSD1) and the histone methyltransferase DOT1L, have been de...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Cusan, Monica, Cai, Sheng F., Mohammad, Helai P., Krivtsov, Andrei, Chramiec, Alan, Loizou, Evangelia, Witkin, Matthew D., Smitheman, Kimberly N., Tenen, Daniel G., Ye, Min, Will, Britta, Steidl, Ulrich, Kruger, Ryan G., Levine, Ross L., Rienhoff, Hugh Y., Koche, Richard P., Armstrong, Scott A.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2018
Pynciau:
Myeloid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5897868/
https://ncbi.nlm.nih.gov/pubmed/29453291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-807024
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg